Cocaine abstinence symptomatology and treatment attrition
about
Anticonvulsants for cocaine dependenceRegulation of dopamine system responsivity and its adaptive and pathological response to stressTopiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial.Predicting complete loss to follow-up after a health-education program: number of absences and face-to-face contact with a researcher.New medications for the treatment of cocaine dependence.Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.Reduced interhemispheric resting state functional connectivity in cocaine addictionChronic stress, drug use, and vulnerability to addiction.Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine.Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.Choosing a behavioral therapy platform for pharmacotherapy of substance users.Illusory predictors: Generalizability of findings in cocaine treatment retention research.Treatment outcome predictors for cocaine dependence.The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study.The runway model of drug self-administration.Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatmentHeterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study.Altered levels of sex and stress steroid hormones assessed daily over a 28-day cycle in early abstinent cocaine-dependent females.Biomarkers for the development of new medications for cocaine dependence.Alcohol, stress, and glucocorticoids: From risk to dependence and relapse in alcohol use disorders.Gender differences in prison-based drug treatment participation.When should we delay highly active antiretroviral therapy?Amantadine treatment for cocaine-dependent patients with severe withdrawal symptoms.Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals.A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disorders.Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors.Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin.Desmopressin accelerates the rate of urinary morphine excretion and attenuates withdrawal symptoms in rats.
P2860
Q24186475-4A1CBB83-8F7C-4FDB-9641-3021C4D0692EQ28081107-5CA91389-B173-42F2-BEB7-C608E1D9EFCDQ30407769-8D789336-A76C-4A52-ABF1-671952F30438Q34060042-043D56B1-EE90-4374-82F9-6EB6CCDEB6DDQ34152650-D79DF43B-07AC-469C-8CD6-00DEAC8A01DAQ34253787-8421C535-405E-44B6-B63A-98C1DD965685Q34256300-72747F39-CDDE-4EB0-A480-3313668D45D1Q34424620-CABEA6EF-9569-4E77-ADFD-46CFF5FB52BBQ34669511-8B8B0663-3235-4CF0-BD36-11A87D560374Q34875333-55D276F5-1A98-4A6C-B68B-BCB56024D217Q35040501-7822764A-B547-4291-BC28-0465755E5A03Q35612732-47A6672C-B033-43FA-B997-9E41DA3CCBA8Q35846758-4733F4E2-CD56-4E54-84E1-4E6200662FDBQ36473498-719BC268-38AD-4AC5-AA54-30BB24EACD62Q36819661-4F48761A-FB64-400B-9426-8E3A68C00C0FQ36847296-3447A033-0D80-4E7E-AA2E-BD6DE7038FE5Q37083836-A5C65169-26A6-4296-A6E7-C9ED19501FB8Q37184684-56C113FC-33F5-4E60-B8DF-0633AEDEE45AQ37348795-772EA631-1BEB-42FB-B35F-7111E98E2626Q37352222-C6270698-661F-4237-ADB6-D6ADABC1FB11Q37379480-DAF42CEC-9D1A-4DE2-BBBA-7E139B2630C4Q38980046-9D9270CA-FF8D-4A41-AE54-A73C2DADAFC0Q39727927-778B9B10-A69E-4175-8FAF-D891DC5A1F65Q42342425-5CC31FA8-1996-46D5-AAD2-FE4F1052322FQ43265607-35A74AB7-F64C-4AF0-97F9-A646008E8834Q47574610-FA8A72C3-83C8-4508-8184-DF6D17841927Q48169882-EAEACF20-2E14-4A9F-945C-E984DBB3489EQ48489385-B06E7A3B-966A-48F1-BC29-40F6E257B5D2Q51745354-2E052676-A881-41C6-AB35-F343B0AC36B4Q52301973-B9F22EA7-03F2-43CA-9AF4-FBEC66622B12
P2860
Cocaine abstinence symptomatology and treatment attrition
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cocaine abstinence symptomatology and treatment attrition
@ast
Cocaine abstinence symptomatology and treatment attrition
@en
Cocaine abstinence symptomatology and treatment attrition
@nl
type
label
Cocaine abstinence symptomatology and treatment attrition
@ast
Cocaine abstinence symptomatology and treatment attrition
@en
Cocaine abstinence symptomatology and treatment attrition
@nl
prefLabel
Cocaine abstinence symptomatology and treatment attrition
@ast
Cocaine abstinence symptomatology and treatment attrition
@en
Cocaine abstinence symptomatology and treatment attrition
@nl
P2093
P1476
Cocaine abstinence symptomatology and treatment attrition
@en
P2093
A I Alterman
C R Boardman
F D Mulvaney
P304
P356
10.1016/S0740-5472(98)00017-8
P407
P577
1999-03-01T00:00:00Z